Management of Enterovirus Infection
Enterovirus infections are primarily managed with supportive care, as no FDA-approved antiviral therapy currently exists, though early intravenous immunoglobulin (IVIG) should be administered promptly in severe neonatal cases and immunocompromised patients to reduce morbidity and mortality. 1, 2
Diagnostic Approach
Specimen Collection Based on Clinical Presentation
The diagnostic strategy must be tailored to the specific clinical syndrome, as viral detection varies significantly by site:
- Meningitis/Encephalitis: Obtain CSF as the primary specimen, but also collect respiratory samples and stool, as EV RNA may be undetectable in CSF while present in other sites 3
- Acute Flaccid Myelitis (AFM)/Paralysis: Respiratory specimens are essential, particularly for EV-D68, which is rarely detected in CSF or stool 3
- Myocarditis: Collect stool, respiratory samples, blood, and consider heart biopsy for confirmation 3
- Hand-Foot-Mouth Disease (HFMD): Vesicle fluid provides the highest viral loads, along with respiratory samples and/or stool 3
- Respiratory disease: Nasopharyngeal aspirates or swabs are recommended 3
- Neonatal sepsis: Obtain blood, CSF, stool, and respiratory samples before administering any blood products including IVIG 3, 1
Diagnostic Testing Method
Use reverse transcriptase PCR (RT-PCR) targeting the 5' non-coding region as the primary diagnostic method due to superior sensitivity, specificity, and rapid turnaround time compared to viral culture. 3, 4
Treatment Strategy
Supportive Care (All Cases)
Management remains primarily supportive for most enterovirus infections, as they are typically self-limited 1, 4
Specific Interventions for Severe Disease
For neonates with severe disease (sepsis, hepatic necrosis with coagulopathy, meningoencephalitis, myocarditis), administer IVIG early in the disease course. 1, 5
Key considerations for IVIG use:
- Most beneficial when given during the first week of life when severe complications typically present 1
- Particularly important in cases with hepatic necrosis, coagulopathy, and/or myocarditis 5
- Clinical efficacy not definitively proven in controlled trials, but observational data suggest benefit 5
Risk Stratification for Severe Disease
Monitor closely for severe disease in neonates with these risk factors:
- Absence of maternal neutralizing antibodies to the infecting serotype 5
- Maternal illness prior to or at delivery 5
- Prematurity 5
- Illness onset within first few days of life 5
- Multiorgan involvement 5
- Infection with high-risk serotypes (group B coxsackieviruses, echovirus 11) 5
Investigational Antiviral Therapy
Pleconaril is an investigational capsid inhibitor that blocks viral attachment and uncoating, showing promise in clinical trials for enterovirus meningitis and severe neonatal disease, though it remains unavailable for routine clinical use 2, 5, 4
Special Populations
Immunocompromised Patients
- Maintain a low threshold for investigation, as clinical presentations can be particularly non-specific and severe 3
- Patients on IgG-depleting therapies (e.g., rituximab) are at especially high risk 3
- These patients may shed enteroviruses in stool for years 3
- Consider early IVIG administration similar to neonatal protocols 1
Critical Pitfalls to Avoid
Do not interpret positive throat or stool specimens as definitive proof of causation, as enteroviruses colonize these sites for weeks to months after acute infection. 3 Correlation with clinical presentation and detection in normally sterile sites (CSF, blood, tissue) is essential for establishing causality.
Do not rely solely on CSF testing for AFM cases or suspected EV-D68 infection, as this virus is rarely detected in CSF. 3 Always obtain respiratory specimens in these clinical scenarios.
Do not delay IVIG administration in severe neonatal cases while awaiting confirmatory testing, as outcomes are time-dependent. 1 Collect baseline blood samples before IVIG administration to avoid interference with subsequent viral detection 3
Infection Control in Healthcare Settings
For hospitalized neonates, implement robust infection control measures immediately upon detection, as healthcare-associated outbreaks can occur with devastating consequences, potentially requiring temporary unit closure 6